Home » Topics » BioWorld Science

BioWorld Science
RSS

Asahi Glass describes novel antiglaucoma difluoroprostaglandins

Oct. 11, 2001

Dainippon compounds with benzodiazepine receptor subtype selectivity

Oct. 11, 2001

Oxamide-based inhibitors of IMPDH under study at Roche

Oct. 11, 2001

Novel combinations claimed by Merck Frosst for depression and anxiety

Oct. 11, 2001

Clinically used pain medication now claimed for IBS

Oct. 11, 2001

Xenova terminates TA-HSV development, DISC-PRO studies continue

Oct. 11, 2001

Novel AEDs validated preclinically available for licensing from ICAgen

Oct. 11, 2001

Orphan Medical submits amended NDA to FDA for Xyrem

Oct. 11, 2001

ICAgen seeks partners for pain management program

Oct. 11, 2001

Orally active, metabolically stable muscarinic M2 antagonist emerges from Schering-Plough screening

Oct. 11, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...